LitCovid-sentences  

PMC:7396557 / 49947-56901 JSONTXT 11 Projects

Annnotations TAB TSV DIC JSON TextAE

Id Subject Object Predicate Lexical cue
T373 0-57 Sentence denotes Relevant Information on the Clinical Application of SFJDC
T374 59-91 Sentence denotes Recommended Therapeutic Regimens
T375 92-216 Sentence denotes SFJDC has been recommended in 15 therapeutic regimens of COVID-19 in China (see detailed information in Tables 1 and 2 ).
T376 218-238 Sentence denotes Ingredients of SFJDC
T377 239-569 Sentence denotes Reynoutria japonica Houtt. (Huzhang), Forsythia suspensa (Thunb.) Vahl (Lianqiao), Isatis tinctoria L. (Banlangen), Bupleurum chinense DC. (Chaihu), Patrinia scabiosifolia Link (Baijiangcao), Verbena officinalis L. (Mabiancao), Phragmites australis (Cav.) Trin. ex Steud. (Lugen), and Glycyrrhiza uralensis Fisch. ex DC. (Gancao).
T378 570-638 Sentence denotes Basic information on SFJDC is provided in the Supplementary Table .
T379 640-692 Sentence denotes Indications for the Treatment of COVID-19 With SFJDC
T380 693-842 Sentence denotes SFJDC is used to treat external wind-heat syndrome during the clinical observation period of COVID-19 and the early stage of the disease (mild case).
T381 843-944 Sentence denotes Indicative symptoms are fever, aversion to cold, cough with yellow phlegm, weakness, and sore throat.
T382 946-991 Sentence denotes Progress of Pharmacological Research on SFJDC
T383 992-1157 Sentence denotes Modern pharmacological studies have found that SFJDC has antiviral, antibacterial, and anti-inflammatory properties and protects against lung injury (see Table 3 ).
T384 1158-1271 Sentence denotes Yanyan Bao et al. evaluated the broad-spectrum antiviral activity of SFJDC by cytopathic effect (CPE) inhibition.
T385 1272-1418 Sentence denotes A total of eight viruses, including H1N1, herpes simplex (HSV), respiratory syncytial virus, adenovirus (ADV) and Coxsackie virus, were evaluated.
T386 1419-1553 Sentence denotes SFJDC had significant in vitro broad-spectrum antiviral activity and the best inhibitory effect was against parainfluenza virus (PIV).
T387 1554-1646 Sentence denotes Similar results were obtained from in vivo experiments (Qiu et al., 2014; Bao et al., 2019).
T388 1647-1770 Sentence denotes Ying Liu et al. used H1N1 FM1 and PR8 strains to induce nasal drip infection in an immunocompromised mouse pneumonia model.
T389 1771-1860 Sentence denotes Therapeutic and preventive effects of SFJDC were observed against H1N1 infection in vivo.
T390 1861-2127 Sentence denotes The results showed that SFJDC influenced the immune function of the mice, improved pneumonia symptoms caused by influenza virus, reduced the lung index of mice infected with H1N1, significantly reduced mortality, and had good therapeutic efficacy (Liu et al., 2010).
T391 2128-2236 Sentence denotes Research by Weiwei Lv et al. found that SFJDC had inhibitory activity against multiple viruses and bacteria.
T392 2237-2326 Sentence denotes Its antiviral activity was inferior to that of Ribavirin, but its cytotoxicity was lower.
T393 2327-2448 Sentence denotes Both antiviral activity and antibacterial action were superior to those of Qingkailing granules (QKLG) (Lv et al., 2013).
T394 2449-2577 Sentence denotes Li Ma et al. used a mouse pneumonia model induced by Streptococcus pneumoniae to study the anti-inflammatory mechanism of SFJDC.
T395 2578-2829 Sentence denotes They discovered that it reduced white blood cell (WBC) count, reduced serum levels of the transcription factor nuclear factor kappa B (NF-κB), MCP-1, inflammatory mediator BK and COX-2, thus, having a therapeutic effect in the model (Ma et al., 2018).
T396 2830-3053 Sentence denotes Further studies found that SFJDC had a significant immune regulatory function, reducing levels of B lymphocytes, CD8+ cells, interleukin-1α (IL-1α), IL-1β, IL-2, IgM, and IgG to improve lung function in mice with pneumonia.
T397 3054-3225 Sentence denotes SFJDC increased the CD4+/CD8+ ratio and number of natural killer (NK) cells, thus, having a therapeutic effect in the pneumonia model (Ma et al., 2019a; Ma et al., 2019b).
T398 3226-3332 Sentence denotes Zhengang Tao et al. observed a protective function of SFJDC against endotoxin LPS-induced rat lung injury.
T399 3333-3450 Sentence denotes Their results showed that SFJDC inhibited the LPS-induced inflammatory response, and reduced LPS-induced lung injury.
T400 3451-3629 Sentence denotes Its mechanism of action might be inhibition of the MAPK (mitogen-activated protein kinase)/NF-κB signaling pathway and downregulation of NF-κB mRNA expression (Tao et al., 2014).
T401 3630-3797 Sentence denotes Yanmei Li et al. used a Pseudomonas aeruginosa (PAK)-induced KM mouse acute lung injury model to explore the mode of action of SFJDC in treatment of acute lung injury.
T402 3798-3957 Sentence denotes They found that SFJDC significantly alleviated lung injury in the model and its mode of action might be related to the ERK signaling pathway (Li et al., 2017).
T403 3959-3985 Sentence denotes Clinical Research on SFJDC
T404 3986-4114 Sentence denotes SFJDC comes from “Detoxification Powder,” and is mainly used to treat fever, parotitis, amygdalitis, plague, and other diseases.
T405 4115-4357 Sentence denotes Recent studies have shown that SFJDC has good clinical efficacy against viral diseases (such as MERS, influenza, human infection with H7N9 avian influenza) and respiratory diseases (such as acute URI, AECOPD, pneumonia, etc.) (see Table 3 ).
T406 4358-4644 Sentence denotes SFJDC has been recommended in diagnosis and treatment schemes such as MERS Diagnosis and Treatment Scheme (Version 2015), China’s Influenza Diagnosis and Treatment Scheme (Version 2019), and Diagnosis and Treatment Scheme for Human Infection with H7N9 Avian Influenza (Version 1, 2017).
T407 4645-4857 Sentence denotes Lei Wang et al. conducted a retrospective analysis of 87 patients with acute URI + fever, and found that patients treated with SFJDC had a significantly higher total response rate than those in the control group.
T408 4858-4962 Sentence denotes SFJDC effectively improved respiratory symptoms in patients with acute URI + fever (Wang and Qiu, 2018).
T409 4963-5234 Sentence denotes In the treatment of community acquired pneumonia (CAP), application of SFJDC shortened recovery time, reduced the duration of fever and reduced the levels of procalcitonin (PCT), CRP, WBC, and other indicators, effectively shortening the course of treatment (Wang, 2016).
T410 5235-5344 Sentence denotes Hongxia Yu et al. evaluated the impact of SFJDC on inflammation-associated cytokines in patients with AECOPD.
T411 5345-5516 Sentence denotes The results showed that SFJDC significantly reduced the levels of interleukin-8 (IL-8), TNF-α, CRP, and PCT, and had significant therapeutic efficacy against AECOPD (Yu H.
T412 5517-5534 Sentence denotes X. et al., 2020).
T413 5535-5726 Sentence denotes Tiling Wang et al. added SFJDC treatment to conventional treatment in 60 mild and moderate AECOPD patients and compared with 60 patients receiving conventional treatment as the control group.
T414 5727-5877 Sentence denotes After 1 week, the treatment group had significantly higher arterial blood gas PaO2 than the control group, without any adverse reactions (Wang, 2015).
T415 5878-6144 Sentence denotes Research showed that treatment of bacterial acute bronchitis and pneumonia with a combination of antibacterial drugs and SFJDC significantly shortened recovery of body temperature, duration of cough and the course of treatment compared with antibacterial drug alone.
T416 6145-6450 Sentence denotes Chunlan Wang et al. observed that combined use of SFJDC and antibiotics significantly improved body temperature, blood sugar, ALT (glutamate transaminase), AST (aspartate aminotransferase) and other indicators compared with the control group, and patients had a higher oxygen index than the control group.
T417 6451-6646 Sentence denotes The results suggested that SFJDC had a significant protective function against lung injury, and the mechanism might be related to inhibition of inflammatory response by SFJDC (Wang et al., 2014).
T418 6648-6673 Sentence denotes Usage and Dosage of SFJDC
T419 6674-6724 Sentence denotes Oral administration, four capsules, 3 times a day.
T420 6726-6752 Sentence denotes Adverse Reactions of SFJDC
T421 6753-6771 Sentence denotes Occasional nausea.
T422 6773-6790 Sentence denotes SFJDC Precautions
T423 6791-6954 Sentence denotes (1) Use is forbidden in those with allergic constitution or who are allergic to the drug. (2) Use is forbidden in those with deficiency-cold in spleen and stomach.